Control of alphavirus-based gene expression using engineered riboswitches

Virology

Volumn 483, Issue , 2015, Pages 302-311

  Bell, Christie L ^a,c   Yu, Dong ^a,c   Smolke, Christina D ^b   Geall, Andrew J ^a,c   Beard, Clayton W ^a,c   Mason, Peter W ^a,d  

^a Novartis Vaccines Inc   (United States)

^b Stanford University   (United States)

^c GLAXOSMITHKLINE   (United States)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Alphavirus; Aptamer; Replicon; Riboswitch; Venezuelan equine encephalitis virus

Indexed keywords

INTERFERON; RIBOZYME; SATELLITE RNA; APTAMER; RIBOSWITCH;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; GENE EXPRESSION REGULATION; GENETIC ENGINEERING; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REPLICON; RIBOSWITCH; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS REPLICATION; VIRUS STRAIN; ALPHAVIRUS; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR BIOLOGY; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ALPHAVIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

ALPHAVIRUS; APTAMERS, NUCLEOTIDE; GENE EXPRESSION REGULATION, VIRAL; GENETIC ENGINEERING; MOLECULAR BIOLOGY; RIBOSWITCH; VIROLOGY; VIRUS REPLICATION;

EID: 84929631056     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.04.023     Document Type: Article

References (26)

1. Alevizatos A.C., McKinney R.W., Feigin R.D. Live, attenuated Venezuelan equine encephalomyelitis virus vaccine. I. Clinical effects in man. Am. J. Trop. Med. Hyg. 1967, 16:762-768.
2. Auslander S., Ketzer P., Hartig J.S. A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. Mol. Biosyst. 2010, 6:807-814.
3. Berger C., Jensen M.C., Lansdorp P.M., Gough M., Elliott C., Riddell S.R. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Investig. 2008, 118:294-305.
4. Bernstein D.I., Reap E.A., Katen K., Watson A., Smith K., Norberg P., Olmsted R.A., Hoeper A., Morris J., Negri S., Maughan M.F., Chulay J.D. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009, 28:484-493.
5. Bonin M., Oberstrass J., Lukacs N., Ewert K., Oesterschulze E., Kassing R., Nellen W. Determination of preferential binding sites for anti-dsRNA antibodies on double-stranded RNA by scanning force microscopy. RNA 2000, 6:563-570.
6. Chang A.L., Wolf J.J., Smolke C.D. Synthetic RNA switches as a tool for temporal and spatial control over gene expression. Curr. Opin. Biotechnol. 2012, 23:679-688.
7. Chen Y.Y., Jensen M.C., Smolke C.D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc. Natl. Acad. Sci. USA 2010, 107:8531-8536.
8. den Boer A.T., Diehl L., van Mierlo G.J., van der Voort E.I., Fransen M.F., Krimpenfort P., Melief C.J., Offringa R., Toes R.E. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance. J. Immunol. 2001, 167:2522-2528.
9. Geall A.J., Verma A., Otten G.R., Shaw C.A., Hekele A., Banerjee K., Cu Y., Beard C.W., Brito L.A., Krucker T., O'Hagan D.T., Singh M., Mason P.W., Valiante N.M., Dormitzer P.R., Barnett S.W., Rappuoli R., Ulmer J.B., Mandl C.W. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 2012, 109:14604-14609.
10. Han S., Asoyan A., Rabenstein H., Nakano N., Obst R. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc. Natl. Acad. Sci. USA 2010, 107:20453-20458.
11. Hsu C., Hughes M.S., Zheng Z., Bray R.B., Rosenberg S.A., Morgan R.A. Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J. Immunol. 2005, 175:7226-7234.
12. Ketzer P., Kaufmann J.K., Engelhardt S., Bossow S., von Kalle C., Hartig J.S., Ungerechts G., Nettelbeck D.M. Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. Proc. Natl. Acad. Sci. USA 2014, 111:E554-E562.
13. Kinney R.M., Chang G.J., Tsuchiya K.R., Sneider J.M., Roehrig J.T., Woodward T.M., Trent D.W. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5[U+05F3]-noncoding region and the E2 envelope glycoprotein. J. Virol. 1993, 67:1269-1277.
14. Kuhn R.J. Togaviridae: the viruses and their replication. Fields Virology 2007, 1002-1023. Lippincott Williams & Wilkins, Philadelphia. 5th edition. D. Howley (Ed.).
15. Liang J.C., Bloom R.J., Smolke C.D. Engineering biological systems with synthetic RNA molecules. Mol. Cell 2011, 43:915-926.
16. Liang J.C., Chang A.L., Kennedy A.B., Smolke C.D. A high-throughput, quantitative cell-based screen for efficient tailoring of RNA device activity. Nucl. Acids Res. 2012, 40:e154.
17. Ljungberg K., Liljestrom P. Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 2015, 14:177-194.
18. Morse M.A., Hobeika A.C., Osada T., Berglund P., Hubby B., Negri S., Niedzwiecki D., Devi G.R., Burnett B.K., Clay T.M., Smith J., Lyerly H.K. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Investig. 2010, 120:3234-3241.
19. Nomura Y., Zhou L., Miu A., Yokobayashi Y. Controlling mammalian gene expression by allosteric hepatitis delta virus ribozymes. ACS Synth. Biol. 2013, 2:684-689.
20. Perri S., Greer C.E., Thudium K., Doe B., Legg H., Liu H., Romero R.E., Tang Z., Bin Q., Dubensky T.W., Vajdy M., Otten G.R., Polo J.M. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 2003, 77:10394-10403.
21. Rayner J.O., Dryga S.A., Kamrud K.I. Alphavirus vectors and vaccination. Rev. Med. Virol. 2002, 12:279-296.
22. Schonborn J., Oberstrass J., Breyel E., Tittgen J., Schumacher J., Lukacs N. Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts. Nucl. Acids Res. 1991, 19:2993-3000.
23. Slovin S.F., Kehoe M., Durso R., Fernandez C., Olson W., Gao J.P., Israel R., Scher H.I., Morris S. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013, 31:943-949.
24. Wecker M., Gilbert P., Russell N., Hural J., Allen M., Pensiero M., Chulay J., Chiu Y.L., Abdool Karim S.S., Burke D.S., Team H.P., Network N.H.V.T. Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults. Clin. Vaccine Immunol. 2012, 19:1651-1660.
25. Win M.N., Smolke C.D. A modular and extensible RNA-based gene-regulatory platform for engineering cellular function. Proc. Natl. Acad. Sci. USA 2007, 104:14283-14288.
26. Yoshioka N., Gros E., Li H.R., Kumar S., Deacon D.C., Maron C., Muotri A.R., Chi N.C., Fu X.D., Yu B.D., Dowdy S.F. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 2013, 13:246-254.